Emerging Options for the Prevention and Management of Clostridioides difficile Infection

• Published in: Drugs (New York, N.Y.) Vol. 83; no. 2; pp. 105 - 116
• Main Authors: Gonzales-Luna, Anne J., Carlson, Travis J., Garey, Kevin W.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.02.2023; Springer Nature B.V
• Subjects: Acids; Anti-Bacterial Agents - therapeutic use; Antibiotics; Bile; Clinical medicine; Clinical practice guidelines; Clinical trials; Clostridioides difficile; Clostridium Infections - drug therapy; Clostridium Infections - prevention & control; Humans; Infections; Internal Medicine; Leading; Leading Article; Medicine; Medicine & Public Health; Microbiomes; Microbiota; Pharmacology/Toxicology; Pharmacotherapy; Prevention; Toxoids - therapeutic use; Vaccines
• ISSN: 0012-6667; 1179-1950
• DOI: 10.1007/s40265-022-01832-x

Agents in development for the prevention or treatment of Clostridioides difficile infection can be split into three broad categories: antibiotics, microbiome restoration, and vaccines. Given the extensive list of agents currently in development, this narrative review will focus on agents that have progressed into late-stage clinical trials, defined as having a Phase III clinical trial registered on ClinicalTrials.gov. These agents include one antibiotic (ridinilazole), three live biotherapeutic products (LBPs) (CP101, RBX2660, and SER109), and two toxoid vaccines (PF06425090 and a second toxoid vaccine). As new prevention and treatment strategies enter the market, clinicians and administrators will need knowledge of these products to make rational decisions on how best to adopt them into clinical practice.